Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

EPO Protein (AA 28-193)

EPO Origin: Human Host: CHO Cells Recombinant > 95 % as analyzed by SDS-PAGE and HPLC. Active
Catalog No. ABIN2017770
  • Target See all EPO Proteins
    EPO (Erythropoietin (EPO))
    Protein Type
    Recombinant
    Biological Activity
    Active
    Protein Characteristics
    AA 28-193
    Origin
    • 14
    • 7
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Source
    • 18
    • 15
    • 7
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    CHO Cells
    Characteristics
    ED50< 1 ng/mL, measured in a cell proliferation assay using TF-1 human erythroleukemic cells, corresponding to a specific activity of >1 x 10^6 units/mg
    Purity
    > 95 % as analyzed by SDS-PAGE and HPLC.
    Endotoxin Level
    < 0.2 EU/μg, determined by LAL method.
  • Application Notes
    Mature human EPO, containing 166 amino acid residues, has a predicted molecular mass of approximately 21 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 26-36 kDa in SDS-PAGE.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Reconstituted in ddH2O or PBS at 100 μg/mL.
    Buffer
    Lyophilized after extensive dialysis against PBS.
    Storage
    -80 °C
    Storage Comment
    Lyophilized recombinant human EPO remains stable up to 6 months at -80 °C from date of receipt. Upon reconstitution, rhEPO should be stable up to 1 week at 4 °C or up to 2 months at -20 °C.
    Expiry Date
    6 months
  • Target
    EPO (Erythropoietin (EPO))
    Abstract
    EPO Products
    Synonyms
    EPO Protein, EP Protein, MVCD2 Protein, erythropoietin Protein, erythropoietin S homeolog Protein, erythropoietin a Protein, EPO Protein, epo Protein, epo.S Protein, Epo Protein, epoa Protein
    Target Type
    Hormone
    Background
    Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.The cDNAs for EPO have been cloned from human, mouse, canine, etc. The mature proteins from the various species are highly conserved, exhibiting greater than 80 % sequence identity at the amino acid level. Human EPO cDNA encodes a 193 amino acid residue precursor protein that is processed to yield a 165 amino acid residue mature protein. EPO contains one O-linked and three N-linked glycosylation sites. Glycosylation of EPO is required for EPO biological activities in vivo. EPO exhibits structural as well as amino sequence identity to the amino terminal 153 amino acid region of thrombopoietin.
    Synonyms: Human EPO-alpha, EPO-alpha, EPO alpha, EPOalpha, h-EPO-alpha, rh-AEPO-alpha, recombinant human EPO-alpha, recombinant EPO-alpha, EPO.
    Molecular Weight
    21 kDa, observed 26-36 kDa in SDS-PAGE.
    Pathways
    JAK-STAT Signaling, Hormone Activity, Negative Regulation of intrinsic apoptotic Signaling, Negative Regulation of Transporter Activity
You are here:
Support